<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03060642</url>
  </required_header>
  <id_info>
    <org_study_id>AAAQ8763</org_study_id>
    <nct_id>NCT03060642</nct_id>
  </id_info>
  <brief_title>The Microenvironment in Barrett's Esophagus</brief_title>
  <acronym>BETRNet2</acronym>
  <official_title>Application of the Microbiome and Microenvironment to Novel Non-Endoscopic Screening and Surveillance in Barrett's Esophagus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to elucidate the relationship between the microbiome, inflammation, and the
      microenvironment in Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC), with the
      end goal of developing a non-endoscopic testing strategy based on pathogenic factors to
      identify patients at highest risk for EAC. To accomplish this the investigators will enroll
      100 patients with known BE (50 with dysplasia or EAC) and 50 subjects without BE undergoing
      upper endoscopy. Prior to endoscopy each subject will undergo three minimally invasive
      potential screening and surveillance tests: saliva (oral microbiome), breath test (exhaled
      volatile organic compounds), and tethered capsule sponge sampling (methylated DNA markers).
      The study will evaluate these novel tests in combination with clinical and anthropometric
      factors to describe an optimal strategy for BE screening and monitoring.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will perform a multi-center cross-sectional study of patients with
      Barrett's esophagus, with and without associated dysplasia or cancer, and controls without
      BE. Enrollment of controls will be stratified based on use of proton pump inhibitors (PPIs).
      The investigators plan to enroll an approximate total of 150 subjects:

      100 BE patients (with or without associated dysplasia or cancer)

        -  50 subjects with non-dysplastic BE

        -  50 subjects with BE and dysplasia or EAC

           50 controls

        -  25 controls on PPIs (at least once daily)

        -  25 controls not taking PPIs

      Various tests will be performed and samples collected on the day of endoscopy. These tests
      include: saliva samples, electronic nose device testing, tethered capsule sponge testing,
      dietary questionnaires, and collection of blood and gastrointestinal biosamples. Analyses of
      this data and samples will then be performed to address the specific aims above.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Oral and esophageal 16S rRNA gene sequencing</measure>
    <time_frame>1 day</time_frame>
    <description>Oral and esophageal microbiome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Esopahgeal tissue RNA-Seq</measure>
    <time_frame>1 day</time_frame>
    <description>Esophageal tissue transcriptome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric aspirate mass spectrometry</measure>
    <time_frame>1 day</time_frame>
    <description>Gastric aspirate bile acid composition</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Barrett Esophagus</condition>
  <condition>Esophageal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Barrett's esophagus</arm_group_label>
    <description>Barrett's esophagus, without or with dysplasia or adenocarcnoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Non-BE endoscopic controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tethered capsule sponge</intervention_name>
    <description>Subjects swallow a tethered capsule sponge sampling device, which is then withdrawn through the mouth after an interval of 5 minutes.</description>
    <arm_group_label>Barrett's esophagus</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
    <other_name>EsophaCap</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electronic nose device</intervention_name>
    <description>Subjects breathe into the device, which then records an exhaled volatile organic compounds (VOC) signature.</description>
    <arm_group_label>Barrett's esophagus</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
    <other_name>Aeonose</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva Gastric Aspirate Tissue from the Esophagus
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with or without Barrett's esophagus already scheduled for upper endoscopy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        (for BE patients)

          -  History of histologically confirmed BE, defined as endoscopically-suspected BE with
             intestinal metaplasia with goblet cells on esophageal biopsies

          -  BE length M≥2

          -  Taking proton pump inhibitors at least once daily for 3 months prior to enrollment

          -  Age ≥18

        Exclusion Criteria:

          -  History of gastric cancer or esophageal squamous cell cancer

          -  History of gastric or esophageal surgery

          -  Use of antibiotics or systemic immunosuppressants within three months prior to the
             date of endoscopy (intranasal and inhaled steroids are allowed)

          -  Known untreated esophageal stricture or uninvestigated dysphagia

          -  Inability to give informed consent

          -  (BE patients only) History of prior endoscopic therapy for BE except a history of
             prior EMR of focal lesions without subsequent ablative therapy is permitted
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julian A. Abrams, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Grisela Compres</last_name>
    <phone>212-304-5606</phone>
    <email>gmc2133@columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lori Lutzke</last_name>
      <email>lutzke.lori@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Prasad Iyer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cadman Leggett</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Griselda Compres</last_name>
      <phone>212-304-5595</phone>
      <email>gmc2133@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Julian Abrams</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Lightdale</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Poneros</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tamas Gonda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maureen Demarshall</last_name>
      <email>demarshm@mail.med.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Falk</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregory Ginsberg</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2017</study_first_submitted>
  <study_first_submitted_qc>February 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Julian A Abrams, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine and Epidemiology</investigator_title>
  </responsible_party>
  <keyword>Microenvironment</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Screening</keyword>
  <keyword>Barrett Esophagus</keyword>
  <keyword>Esophageal Adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Barrett Esophagus</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

